ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run

We recently published 10 Big Names With Painful Declines. ImmunityBio Inc. (NASDAQ:IBRX) was one of the worst performers on Tuesday.

ImmunityBio extended losses for a third day on Tuesday, shedding 4.19 percent to close at $5.95 apiece as investors continued to take profits after recording 14 straight days of gains last week.

For the entire month of January until Thursday, January 22, ImmunityBio Inc. (NASDAQ:IBRX) has already soared by 271 percent following a flurry of positive developments, including strong clinical trial results, a 700 percent sales jump from its therapy Anktiva, and expansion into international markets.

In other news, ImmunityBio Inc. (NASDAQ:IBRX) is set to announce detailed results of its QUILT-3.078 Phase 2 study evaluating a chemotherapy-free combination immunotherapy regimen in patients with second-line recurrent or progressive glioblastoma (GBM), as well as patients treated under single-patient INDs (spINDs) across first- to third-line disease.

As of last Thursday, the study has enrolled 23 patients with recurrent or progressive GBM who progressed following standard-of-care therapy, including surgery, radiation, and temozolomide-based chemotherapy.

Photo by National Cancer Institute on Unsplash

The treatment has also demonstrated a manageable safety profile

Of the total number of enrollees, 19 remain alive, with four deaths reported to date.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.